{"id":38843,"date":"2026-07-17T17:00:00","date_gmt":"2026-07-17T15:00:00","guid":{"rendered":"http:\/\/stocks-future.com\/?guid=9fe99a532e6a1b34984425eee4d0cafb"},"modified":"2026-07-17T17:00:00","modified_gmt":"2026-07-17T15:00:00","slug":"iveena-delivery-systems-announces-successful-completion-of-phase-1-clinical-study-of-ivmed-85","status":"publish","type":"post","link":"https:\/\/stocks-future.com\/?p=38843","title":{"rendered":"iVeena Delivery Systems Announces Successful Completion of Phase 1 Clinical Study of IVMED-85"},"content":{"rendered":"<p>\n<i>IVMED-85 demonstrated a favorable safety and tolerability profile in healthy adult volunteers, supporting advancement toward Phase 2 clinical development for pediatric myopia<\/i><\/p><br\/><a href=\"https:\/\/mms.businesswire.com\/media\/20260716184652\/en\/2854064\/5\/iVeena_primary.jpg\"><img src=\"https:\/\/mms.businesswire.com\/media\/20260716184652\/en\/2854064\/22\/iVeena_primary.jpg\" \/><\/a><br\/><a href=\"https:\/\/mms.businesswire.com\/media\/20260716184652\/en\/2854064\/5\/iVeena_primary.jpg\"><img src=\"https:\/\/mms.businesswire.com\/media\/20260716184652\/en\/2854064\/21\/iVeena_primary.jpg\" \/><\/a><p>SALT LAKE CITY--(BUSINESS WIRE)--iVeena Delivery Systems, Inc., (\u201ciVeena\u201d) a clinical-stage ophthalmic biopharmaceutical company, today announced the successful completion of its Phase 1 clinical trial evaluating the safety of IVMED-85, an investigational, preservative-free ophthalmic solution being developed for the treatment of pediatric myopia. iVeena has completed the first-in-human, randomized, double-masked, vehicle-controlled Phase 1 study, which demonstrated a favorable safety profile and supports the continued clinical development of IVMED-85 into Phase 2 studies.<\/p><p>\nThe Phase 1 trial enrolled 36 healthy adult volunteers who were randomized 1:1 to receive either IVMED-85 or vehicle twice daily for six weeks.<\/p><p>\nKey findings from the Phase 1 study include:<\/p><ul class=\"bwlistdisc\">\n<li>\nAll 36 randomized subjects successfully completed the study.<\/li>\n<li>\nNo serious adverse events or adverse events of special interest were observed.<\/li>\n<li>\nOcular treatment-emergent adverse events (e.g., irritation, hyperemia, pruritus) were all mild, transient, and self-limited, resolving without intervention.<\/li>\n<li>\nNo clinically significant changes were observed in visual acuity, intraocular pressure, corneal or conjunctival fluorescein staining, intraocular inflammation, or dilated fundus examinations.<\/li>\n<\/ul><p>\n\"The successful completion of our first-in-human clinical study represents an important milestone for iVeena and supports the continued development of IVMED-85,\" said Bala Ambati, MD, PhD, MBA, President and Chief Medical Officer of iVeena. \"These results provide encouraging evidence that our novel lysyl oxidase activation approach with IVMED-85, a new chemical entity, was well tolerated in healthy volunteers and supports our confidence as we prepare to advance into Phase 2 clinical evaluation in children with progressive myopia.\"<\/p><p>\nUnlike other pharmacologic approaches that rely on muscarinic receptor antagonism, IVMED-85 is designed to activate lysyl oxidase (LOX), a naturally occurring copper-dependent enzyme responsible for collagen crosslinking within the sclera, which is reduced in children with myopia. By restoring the biomechanical integrity of the sclera, IVMED-85 directly addresses a pathophysiological mechanism believed to contribute to axial elongation and myopic progression.<\/p><p>\n\"Our objective has always been to develop a therapy that treats the underlying mechanisms of myopia progression rather than simply managing its symptoms,\" said Sarah Molokhia, RPh, PhD, Chief Scientific Officer of iVeena. \"Completion of this Phase 1 study provides an important foundation for the next stage of development and another meaningful step toward bringing a differentiated treatment option to children affected by progressive myopia.\"<\/p><p>\nCompletion of the trial represents an important milestone as iVeena prepares for continued interactions with the U.S. Food and Drug Administration regarding the future clinical development of IVMED-85. The Company is actively advancing preparations for its Phase 2 pediatric clinical program designed to evaluate the dosing, safety, and efficacy of IVMED-85 in children with progressive myopia.<\/p><p>\n<b>About IVMED-85<\/b><\/p><p>\nLead program IVMED-85 is a new chemical entity (NCE), preservative-free prescription eye drop to prevent myopic progression. IVMED-85 is a non-surgical, non-invasive, non-atropine daily eye drop that strengthens scleral and corneal collagen crosslinks through LOX activation, potentially leading to improved refraction and a decrease in the rate of axial elongation.<\/p><p>\n<b>About iVeena<\/b><\/p><p>\niVeena Delivery Systems, Inc. is a privately held, clinical stage ophthalmology company developing disease-modifying pharmacologic innovations for refractive diseases. iVeena previously licensed to Glaukos, Inc, lead asset, IVMED-80, an Orphan Drug Designated eye drop for keratoconus. iVeena is developing IVMED-85, a first-in-class, investigational eye drop formulation for pediatric myopia.<\/p><br\/> <b>Contacts<\/b> <br\/><p>\niVeena Delivery Systems, Inc.\n<br\/>Email: <a  href=\"mailto:press@iveenamed.com\" rel=\"nofollow\" shape=\"rect\">press@iveenamed.com<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>IVMED-85 demonstrated a favorable safety and tolerability profile in healthy adult volunteers, supporting advancement toward Phase 2 clinical development for pediatric myopiaSALT LAKE CITY&#8211;(BUSINESS WIRE)&#8211;iVeena Delivery Systems, Inc., (\u201ciVeena\u201d) a &#8230;<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-38843","post","type-post","status-publish","format-standard","hentry","category-infos-businesswire"],"_links":{"self":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/38843","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=38843"}],"version-history":[{"count":1,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/38843\/revisions"}],"predecessor-version":[{"id":38844,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/38843\/revisions\/38844"}],"wp:attachment":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=38843"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=38843"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=38843"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}